Upon our 50th anniversary as a business in the pharmaceutical industry, we reiterate our commitment to promoting health and wellbeing, improving the quality of life of the Brazilian population and that of our consumers in the 12 countries to which we export
Our portfolio includes prescription and over-the-counter medica – tion, generics, dermatological products, nutraceuticals and probiotics, covering over 23 medical specialties and 139 therapeutic classes.
To develop innovative products with proven efficacy and security, we as – sociated our investments in R&D and innovation with performance geared to serving unmet needs. In doing so, we enabled a balanced supply of the best available health solutions for our busi – ness partners, physicians, consumers, communities and suppliers, creating value for everyone.
A 100% Brazilian-owned company, Aché has led the market in prescrip – tion medication since 2007 through our three industrial units – in Guarulhos (SP), São Paulo (SP) and Anápolis (GO). With nationwide reach, our Sales and Demand Generation Forces keep us in touch with health professionals and Brazil’s main points of sale.
In addition with our own operations, Aché has stakes in Melcon Indústria Farmacêutica, a provider of hormonebased medication, and Bionovis Brasil, a Brazilian joint venture devoted to R&D in the field of biotechnological pharmaceuticals.
The results we have achieved and the market position Aché has attained evince the effectiveness of our performance model in our competitive environment. Net sales rose by 9.3% last year in comparison with 2014. In – vestments in employee training were 29% higher than in the preceding year.
The creation of our centers for incremental and radical innovaTion and the opening of our molecular design and synthesis laboratory are important steps aché has taken in order to grow sustainably in the following years